Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543918 · ClinicalTrials.gov registry record · Phase 1
A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT02543918 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 84 participants.
The verdict
NCT02543918, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.
Interventions
- DRUG Ixekizumab
- DRUG Boostrix®
- DRUG Pneumovax®23
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2015-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02543918
The ClinicalTrials.gov registry entry for NCT02543918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ixekizumab is the first listed.
NCT02543918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02543918 about?
NCT02543918 is a clinical study titled "A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants". The purpose of this study is to compare the body's immune response when vaccines are given alone versus when vaccines are given along with the study drug called ixekizumab. The vaccines protect against pneumonia and tetanus. This study will last about 6 weeks with follow-up at 12 weeks.
What is the current status of trial NCT02543918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2015-09. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02543918?
The interventions under investigation include: Ixekizumab (DRUG), Boostrix® (DRUG), Pneumovax®23 (DRUG).
Who is sponsoring clinical trial NCT02543918?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.